Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer

The challenge of value-based pricing in combination therapy: the case of trastuzumab and pertuzumab in HER2+ metastatic breast cancer

(2021) Boshen Jiao et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore

(2021) Li-Jen Cheng et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Potential non-drug cost differences associated with the use of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment of HER2-positive early breast cancer patients in Western Europe and the United States.

(2021) Federico Manevy et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessing the efficacy‐effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population‐based, real‐world data for contemporary parenteral cancer therapeutics

(2020) Cameron M. Phillips et al.   CANCER

Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

(2020) Kelvin Chan et al.   BMJ Open

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada

(2020) Wei Fang Dai et al.   BMC CANCER

Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes

(2020) Inna Y. Gong et al.   BREAST CANCER RESEARCH AND TREATMENT

Dual HER2 blockade in the first-line treatment of metastatic breast cancer - A retrospective population-based observational study in Danish patients

(2020) Thomas Christensen et al.   BREAST

Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time

(2018) Ronak Saluja et al.   Journal of Oncology Practice

The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)

(2018) Sinéad M Langan et al.   BMJ-British Medical Journal

Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer

(2017) Henry W. C. Leung et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Phase-specific and lifetime costs of cancer care in Ontario, Canada

(2016) Claire de Oliveira et al.   BMC CANCER

Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

(2016) Ben Y. Durkee et al.   JOURNAL OF CLINICAL ONCOLOGY

Unknown

(2015)   CLINICAL PHARMACOLOGY & THERAPEUTICS

Adjusting for Baseline Covariates in Net Benefit Regression: How You Adjust Matters

(2015) Wanrudee Isaranuwatchai et al.   PHARMACOECONOMICS

Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer

(2014) Nigel Fleeman et al.   PHARMACOECONOMICS

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

(2013) Sandra M Swain et al.   LANCET ONCOLOGY

Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force

(2013) Don Husereau et al.   VALUE IN HEALTH

Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force

(2013) Louis P. Garrison et al.   VALUE IN HEALTH

Projections of the Cost of Cancer Care in the United States: 2010-2020

(2011) A. B. Mariotto et al.   JNCI-Journal of the National Cancer Institute

An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

(2011) Peter C. Austin   MULTIVARIATE BEHAVIORAL RESEARCH

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

(2009) Peter C. Austin   STATISTICS IN MEDICINE

Interpreting the Results of Cost-Effectiveness Studies

(2008) David J. Cohen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY